Year |
Citation |
Score |
2020 |
Petővári G, Dankó T, Tőkés AM, Vetlényi E, Krencz I, Raffay R, Hajdu M, Sztankovics D, Németh K, Vellai-Takács K, Jeney A, Kulka J, Sebestyén A. In Situ Metabolic Characterisation of Breast Cancer and Its Potential Impact on Therapy. Cancers. 12. PMID 32899149 DOI: 10.3390/Cancers12092492 |
0.303 |
|
2019 |
Petővári G, Dankó T, Krencz I, Hujber Z, Rajnai H, Vetlényi E, Raffay R, Pápay J, Jeney A, Sebestyén A. Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. Pathology Oncology Research : Por. PMID 31187466 DOI: 10.1007/S12253-019-00677-2 |
0.358 |
|
2018 |
Petővári G, Hujber Z, Krencz I, Dankó T, Nagy N, Tóth F, Raffay R, Mészáros K, Rajnai H, Vetlényi E, Takács-Vellai K, Jeney A, Sebestyén A. Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells. Cancer Cell International. 18: 211. PMID 30574020 DOI: 10.1186/S12935-018-0710-0 |
0.365 |
|
2018 |
Krencz I, Sebestyen A, Papay J, Jeney A, Hujber Z, Burger CD, Keller CA, Khoor A. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis. Human Pathology. PMID 29885404 DOI: 10.1016/J.Humpath.2018.05.018 |
0.359 |
|
2018 |
Sebestyén A, Hujber Z, Petővári G, Krencz I, Dankó T, Horváth G, Mészáros K, Rajnai H, Tretter L, Jeney A. Substrate oxidation differences in human glioma cells and their potential clinical significance Biochimica Et Biophysica Acta (Bba) - Bioenergetics. 1859: e104. DOI: 10.1016/J.Bbabio.2018.09.309 |
0.307 |
|
2017 |
Hujber Z, Petővári G, Szoboszlai N, Dankó T, Nagy N, Kriston C, Krencz I, Paku S, Ozohanics O, Drahos L, Jeney A, Sebestyén A. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells. Journal of Experimental & Clinical Cancer Research : Cr. 36: 74. PMID 28578659 DOI: 10.1186/S13046-017-0544-Y |
0.312 |
|
2016 |
Jeney A, Hujber Z, Szoboszlai N, Fullár A, Oláh J, Pap É, Márk Á, Kriston C, Kralovánszky J, Kovalszky I, Vékey K, Sebestyén A. Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells. Cancer Cell International. 16: 4. PMID 26869854 DOI: 10.1186/S12935-016-0281-X |
0.34 |
|
2015 |
Harisi R, Jeney A. Extracellular matrix as target for antitumor therapy. Oncotargets and Therapy. 8: 1387-98. PMID 26089687 DOI: 10.2147/Ott.S48883 |
0.761 |
|
2012 |
Péterfia B, Füle T, Baghy K, Szabadkai K, Fullár A, Dobos K, Zong F, Dobra K, Hollósi P, Jeney A, Paku S, Kovalszky I. Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2. Plos One. 7: e39474. PMID 22745764 DOI: 10.1371/Journal.Pone.0039474 |
0.431 |
|
2011 |
Harisi R, Szekely G, Jeney A. Molecular targets in antimetastatic therapy of gastrointestinal tumors Zeitschrift FüR Gastroenterologie. 49. DOI: 10.1055/s-0031-1278454 |
0.715 |
|
2010 |
Réti A, Pap E, Adleff V, Jeney A, Kralovánszky J, Budai B. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase. Cancer Chemotherapy and Pharmacology. 66: 219-27. PMID 19830428 DOI: 10.1007/S00280-009-1149-8 |
0.307 |
|
2010 |
Harisi R, Székely G, Járay B, Winternitz T, Harsányi L, Kupcsulik P, Jeney A, Weltner J. The prognostic value of cell proliferation in colorectal adenomas and carcinomas Zeitschrift FüR Gastroenterologie. 48. DOI: 10.1055/s-0030-1254765 |
0.719 |
|
2009 |
Harisi R, Kenessey I, Olah JN, Timar F, Babo I, Pogany G, Paku S, Jeney A. Differential inhibition of single and cluster type tumor cell migration. Anticancer Research. 29: 2981-5. PMID 19661304 |
0.73 |
|
2009 |
Hauser P, Hanzély Z, Máthé D, Szabó E, Barna G, Sebestyén A, Jeney A, Schuler D, Fekete G, Garami M. Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study. Pediatric Hematology and Oncology. 26: 363-74. PMID 19579083 DOI: 10.1080/08880010902973293 |
0.347 |
|
2009 |
Réti A, Barna G, Pap E, Adleff V, L Komlósi V, Jeney A, Kralovánszky J, Budai B. Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells. Pathology Oncology Research : Por. 15: 335-44. PMID 19048402 DOI: 10.1007/S12253-008-9126-9 |
0.372 |
|
2007 |
Harisi R, Dudas J, Nagy-Olah J, Timar F, Szendroi M, Jeney A. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function. Cancer Biology & Therapy. 6: 1240-6. PMID 17703109 DOI: 10.4161/Cbt.6.8.4443 |
0.73 |
|
2006 |
Péterfia B, Hollósi P, Szilák L, Timár F, Paku S, Jeney A, Kovalszky I. [Role of syndecan-1 proteoglycan in the invasiveness of HT-1080 fibrosarcoma]. Magyar Onkologia. 50: 115-20. PMID 16888674 |
0.344 |
|
2006 |
Jeney A, Kenessey I, Timár F, Oláh J, Pogány G, Babó I, Harisi R. [Study of drugs against neoplastic metastasis]. Magyar Onkologia. 50: 93-100. PMID 16888671 |
0.724 |
|
2006 |
Harisi R, Dudás J, Pogány G, Timár F, Oláh JN, Szendroi M, Jeney A. Repopulation of osteosarcoma cells after treatment with doxorubicin in the presence of extracellular matrix biopolymers. Cancer Chemotherapy and Pharmacology. 58: 334-42. PMID 16534616 DOI: 10.1007/S00280-005-0165-6 |
0.749 |
|
2005 |
Harisi R, Dudás J, Timár F, Pogány G, Timár J, Kovalszky I, Szendroi M, Jeney A. Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture Cell Biology International. 29: 959-967. PMID 16242975 DOI: 10.1016/J.Cellbi.2005.08.010 |
0.774 |
|
2005 |
Harisi R, Dudás J, Tímár F, Pogány G, Paku S, Tímár J, Kovalszky I, Szendroi M, Jeney A. Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix. Anticancer Research. 25: 805-13. PMID 15868912 |
0.766 |
|
2003 |
Tímár J, Ladányi A, Peták I, Jeney A, Kopper L. Molecular pathology of tumor metastasis III. Target array and combinatorial therapies. Pathology Oncology Research : Por. 9: 49-72. PMID 12704448 DOI: 10.1007/Bf03033715 |
0.363 |
|
2002 |
Tímár J, Csuka O, Orosz Z, Jeney A, Kopper L. Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis. Pathology Oncology Research : Por. 8: 204-19. PMID 12516003 DOI: 10.1007/Bf03032397 |
0.312 |
|
2002 |
Kralovánszky J, Köves I, Orosz Z, Katona C, Tóth K, Rahóty P, Czeglédi F, Kovács T, Budai B, Hullán L, Jeney A. Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. Oncology. 62: 167-74. PMID 11914603 DOI: 10.1159/000048263 |
0.314 |
|
2002 |
Tímár J, Csuka O, Orosz Z, Jeney A, Kopper L. Molecular pathology of tumor metastasis. I. Predictive pathology. Pathology Oncology Research : Por. 7: 217-30. PMID 11692150 DOI: 10.1007/Bf03032353 |
0.37 |
|
2001 |
Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S, Bocsi J, Jeney A, Laurie GW. Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology. 60: 274-81. PMID 11340380 DOI: 10.1159/000055329 |
0.764 |
|
1999 |
Katona C, Tímár F, Jeney A, Fischel JL, Milano G, Pandi E, Kralovánszky J. Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities. Anti-Cancer Drugs. 10: 561-7. PMID 10885904 DOI: 10.1097/00001813-199907000-00008 |
0.388 |
|
1999 |
Babó I, Bocsi J, Jeney A. The site-dependent growth characteristics of a human xenotransplanted basaloid squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. 125: 35-41. PMID 10037275 DOI: 10.1007/S004320050239 |
0.737 |
|
1999 |
Schaff Z, Kovalszky I, Nagy P, Zalatnai A, Jeney A, Lapis K. Human and experimental hepatocarcinogenesis. Scandinavian Journal of Gastroenterology. Supplement. 228: 90-7. PMID 9867118 DOI: 10.1080/003655298750026615 |
0.322 |
|
1998 |
Babó I, Zalatnai A, Schaff Z, Suba Z, Szabó G, Jeney A. The pathomorphology of a human xenotransplanted basaloid squamous cell carcinoma. Neoplasma. 45: 210-5. PMID 9890663 |
0.36 |
|
1998 |
Kovalszky I, Dudás J, Oláh-Nagy J, Pogány G, Töváry J, Timár J, Kopper L, Jeney A, Iozzo RV. Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Molecular and Cellular Biochemistry. 183: 11-23. PMID 9655174 DOI: 10.1023/A:1006898920637 |
0.323 |
|
1998 |
Ladányi A, Nagy JO, Jeney A, Tímár J. Cytokine sensitivity of metastatic human melanoma cell lines-- simultaneous inhibition of proliferation and enhancement of gelatinase activity. Pathology Oncology Research : Por. 4: 108-14. PMID 9654595 DOI: 10.1007/Bf02904703 |
0.348 |
|
1998 |
Timár F, Botyánszki J, Süli-Vargha H, Babó I, Oláh J, Pogány G, Jeney A. The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site. Cancer Chemotherapy and Pharmacology. 41: 292-8. PMID 9488598 DOI: 10.1007/S002800050742 |
0.707 |
|
1997 |
Kovalszky, Nagy JO, Gallai M, Sebestyén A, Schaff Z, Paku S, Jeney A, Iozzo RV. Altered Proteoglycan Gene Expression in Human Biliary Cirrhosis. Pathology Oncology Research : Por. 3: 51-58. PMID 11173626 DOI: 10.1007/Bf02893354 |
0.303 |
|
1997 |
Jeney A, Kovalszky I, Timár F, Schaff Z, Zalatnai A, Lapis K, Oláh J, Divald A, Szende B. Modification of pathobiological events by potential hepatopharmacological agents Inflammopharmacology. 5: 93-103. DOI: 10.1007/Bf02679010 |
0.336 |
|
1996 |
Tímár J, Tóvári J, Pogány G, Ladányi A, Paku S, Rśó E, Bocsi J, Jeney A, Lapis K. The antimetabolite Tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells. European Journal of Cancer (Oxford, England : 1990). 152-9. PMID 8695225 DOI: 10.1016/0959-8049(95)00544-7 |
0.466 |
|
1995 |
Timár J, Jeney A, Kovalszky, Kopper L. Role of Proteoglycans in Tumor Progression. Pathology Oncology Research : Por. 1: 85-93. PMID 11173574 DOI: 10.1007/Bf02893590 |
0.409 |
|
1995 |
Jeney A, Kovalszky I, Rásó E, Durand RE, Fürész J, Lapis K. The biological activity of cisplatin and dibromodulcitol in combination therapy. British Journal of Cancer. 71: 317-21. PMID 7841047 DOI: 10.1038/Bjc.1995.63 |
0.377 |
|
1992 |
Kovalszky I, Szeberenyi S, Zalatnai A, Vincze I, Lapis K, Jeney A. Modification of DENA-induced hepatocarcinogenesis by CCl4 cirrhosis. Comparison of the marker enzyme patterns. Carcinogenesis. 13: 773-8. PMID 1350234 DOI: 10.1093/Carcin/13.5.773 |
0.314 |
|
1991 |
Timár J, Pogány G, Balázs M, Szöllösi J, Ladányi A, Oláh J, Timár F, Lapis K, Jeney A. Modulation of membrane phenotype, matrix adhesion and microinvasiveness of metastatic tumour cells by HUdR. Cell Biochemistry and Function. 8: 211-20. PMID 2272119 DOI: 10.1002/Cbf.290080405 |
0.302 |
|
1991 |
Kovalszky I, Kralovánszky J, Jeney A, Lapis K, Karácsonyi S, Széchény A. Alkaline phosphatase activity in human and rat liver tumors. Oncology. 48: 144-8. PMID 1847742 DOI: 10.1159/000226914 |
0.345 |
|
1984 |
Kopper L, Magyarosy E, Jeney A, Lapis K, Szabolcs A, Otvös L. Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts. Oncology. 41: 155-8. PMID 6328393 DOI: 10.1159/000225813 |
0.349 |
|
1978 |
Kopper L, Jeney A, Lapis K, Török M. Studies of the growth of an ascitic tumour. II. A system to study the tumour-age dependent effect of antitumour agents. European Journal of Cancer. 14: 75-82. PMID 624305 DOI: 10.1016/0014-2964(78)90140-8 |
0.317 |
|
1978 |
Kopper L, Jeney A, Takács J, Benedeczky I, Dzurillay E, Lapis K. Studies of the growth of an ascitic tumour. I. Cellular and subcellular changes during the tumour growth. European Journal of Cancer. 14: 59-73. PMID 624304 DOI: 10.1016/0014-2964(78)90139-1 |
0.335 |
|
1976 |
Kopper L, Jeney A, Ferencz G, Lapis K, Szende B. Studies on in vitro carcinogenesis. I. Autoradiographic and biochemical study on the incorporation of labelled methylcholantrene into mouse embryonic cells. Zeitschrift Fur Krebsforschung Und Klinische Onkologie. Cancer Research and Clinical Oncology. 85: 117-24. PMID 130740 DOI: 10.1007/Bf00304944 |
0.33 |
|
Show low-probability matches. |